• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

奥马珠单抗可改善重度哮喘患者的一秒用力呼气容积。

Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma.

作者信息

Pałgan Krzysztof, Żbikowska-Götz Magdalena, Lis Kinga, Chrzaniecka Elżbieta, Bartuzi Zbigniew

机构信息

Department of Allergy, Clinical Immunology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.

出版信息

Postepy Dermatol Alergol. 2018 Oct;35(5):495-497. doi: 10.5114/ada.2018.77241. Epub 2018 Jul 19.

DOI:10.5114/ada.2018.77241
PMID:30429708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6232554/
Abstract

INTRODUCTION

Asthma is a multiphenotypic disease, and therapeutic managenment in patients with severe asthma is particulary difficult, with conventional treatment of severe asthma showing poor efficacy.

AIM

To analyse forced expiratory volume in 1 s (FEV) following the adminstration of omalizumab.

MATERIAL AND METHODS

Six patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.

RESULTS

Treatment with omalizumab increased in all subjects FEV by 17.28 ±13.4% after months and 18.57 ±13.4% after 12 months of treatment.

CONCLUSIONS

These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.

摘要

引言

哮喘是一种多表型疾病，重度哮喘患者的治疗管理尤其困难，重度哮喘的传统治疗效果不佳。

目的

分析使用奥马珠单抗后1秒用力呼气容积（FEV）。

材料与方法

根据全球哮喘防治创议（GINA）指南，纳入6例重度、未控制哮喘患者（平均年龄：50±12.6岁）进行研究。

结果

所有受试者使用奥马珠单抗治疗数月后FEV增加17.28±13.4%，治疗12个月后增加18.57±13.4%。

结论

这些结果进一步证明，奥马珠单抗治疗可改善重度哮喘患者的肺功能参数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e173/6232554/cdb1d577eca7/PDIA-35-77241-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e173/6232554/fdb8b667e7fe/PDIA-35-77241-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e173/6232554/f913acc2f924/PDIA-35-77241-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e173/6232554/cdb1d577eca7/PDIA-35-77241-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e173/6232554/fdb8b667e7fe/PDIA-35-77241-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e173/6232554/f913acc2f924/PDIA-35-77241-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e173/6232554/cdb1d577eca7/PDIA-35-77241-g003.jpg

相似文献

1
Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma.奥马珠单抗可改善重度哮喘患者的一秒用力呼气容积。
Postepy Dermatol Alergol. 2018 Oct;35(5):495-497. doi: 10.5114/ada.2018.77241. Epub 2018 Jul 19.
2
Omalizumab Treatment for Atopic Severe Persistant Asthma: A Single-Center, Long-Term, Real-Life Experience with 38 Patients.奥马珠单抗治疗特应性重度持续性哮喘：38例患者的单中心长期真实世界经验
Turk Thorac J. 2018 Sep 13;19(4):187-192. doi: 10.5152/TurkThoracJ.2018.17109. Print 2018 Oct.
3
Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.重度过敏性哮喘患者长期奥马珠单抗治疗的评估——重度哮喘的长期奥马珠单抗治疗
J Asthma. 2013 Aug;50(6):687-94. doi: 10.3109/02770903.2013.792348. Epub 2013 May 9.
4
Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.奥马珠单抗在各年龄段重度哮喘患者中的疗效：意大利的真实病例经验
Respir Med. 2016 Oct;119:141-149. doi: 10.1016/j.rmed.2016.09.005. Epub 2016 Sep 4.
5
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.根据患者特征，重度嗜酸性粒细胞性哮喘换用美泊利珠单抗相比于奥马珠单抗的获益。
Respir Res. 2021 May 10;22(1):144. doi: 10.1186/s12931-021-01733-9.
6
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.对于重度持续性哮喘患者，尽管接受了最佳可用治疗（《全球哮喘防治创议》2002版第4步治疗）但控制不佳时，奥马珠单抗作为附加治疗的益处：INNOVATE研究。
Allergy. 2005 Mar;60(3):309-16. doi: 10.1111/j.1398-9995.2004.00772.x.
7
Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.生物标志物与奥马珠单抗治疗变应性哮喘患者真实世界结局相关性的回顾性研究。
Clin Ther. 2019 Oct;41(10):1956-1971. doi: 10.1016/j.clinthera.2019.07.021. Epub 2019 Sep 25.
8
Lung function parameters in omalizumab responder patients: An interesting tool?奥马珠单抗应答患者的肺功能参数：一个有趣的工具？
Allergy. 2017 Dec;72(12):1953-1961. doi: 10.1111/all.13202. Epub 2017 Jun 14.
9
Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.基于人群的奥马珠单抗治疗标准治疗控制不佳的重度哮喘患者的疗效模型。
AAPS J. 2013 Apr;15(2):559-70. doi: 10.1208/s12248-013-9463-9. Epub 2013 Feb 15.
10
Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA.奥马珠单抗治疗固定气道阻塞型哮喘：EXTRA 的事后分析。
J Allergy Clin Immunol Pract. 2022 Jan;10(1):222-228. doi: 10.1016/j.jaip.2021.08.006. Epub 2021 Aug 19.

引用本文的文献

1
Four-week IgE/baseline IgE ratio combined with tryptase predicts clinical outcome in omalizumab-treated children with moderate-to-severe asthma.四周的免疫球蛋白E/基线免疫球蛋白E比值联合类胰蛋白酶可预测接受奥马珠单抗治疗的中重度哮喘儿童的临床结局。
Open Med (Wars). 2025 May 21;20(1):20251176. doi: 10.1515/med-2025-1176. eCollection 2025.

本文引用的文献

1
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.波兰使用奥马珠单抗治疗重度过敏性哮喘项目的有效性：单中心经验
BMC Pulm Med. 2016 Apr 26;16(1):61. doi: 10.1186/s12890-016-0224-2.
2
Intrasubject Variability in Total IgE Levels in Patients with Moderate to Severe Persistent Allergic Asthma Over 1 Year.中度至重度持续性过敏性哮喘患者1年内总IgE水平的个体内变异性
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):691-696.e1. doi: 10.1016/j.jaip.2016.02.007. Epub 2016 Mar 30.
3
Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.
奥马珠单抗对合并或不合并慢性鼻-鼻窦炎的过敏性哮喘患者肺功能的不同影响。
Allergy Asthma Proc. 2016 Jan-Feb;37(1):23-6. doi: 10.2500/aap.2016.37.3923.
4
Classification of Asthma Based on Nonlinear Analysis of Breathing Pattern.基于呼吸模式非线性分析的哮喘分类
PLoS One. 2016 Jan 29;11(1):e0147976. doi: 10.1371/journal.pone.0147976. eCollection 2016.
5
Determinants of uncontrolled asthma in a Swedish asthma population: cross-sectional observational study.瑞典哮喘人群中哮喘控制不佳的决定因素：横断面观察性研究。
Eur Clin Respir J. 2014 Sep 12;1. doi: 10.3402/ecrj.v1.24109. eCollection 2014.
6
The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.波兰变态反应学会关于使用奥马珠单抗治疗严重IgE介导的过敏性哮喘的治疗方案必要变更的声明。
Pneumonol Alergol Pol. 2015;83(4):335-8. doi: 10.5603/PiAP.2015.0053.
7
Angiogenesis in bronchial asthma.支气管哮喘中的血管生成
Int J Immunopathol Pharmacol. 2015 Sep;28(3):415-20. doi: 10.1177/0394632015580907. Epub 2015 Apr 1.
8
Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.奥马珠单抗治疗持续性未控制过敏性哮喘患者的长期疗效和安全性：一项系统评价和荟萃分析。
Sci Rep. 2015 Feb 3;5:8191. doi: 10.1038/srep08191.
9
Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients.支气管活检的蛋白质组学：半乳糖凝集素-3作为奥马珠单抗治疗的重度哮喘患者气道重塑调节的预测生物标志物
Immunol Lett. 2014 Nov;162(1 Pt A):2-10. doi: 10.1016/j.imlet.2014.08.010. Epub 2014 Sep 3.
10
Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.奥马珠单抗可调节严重持续性过敏性哮喘患者的支气管网状基底膜厚度和嗜酸性粒细胞浸润。
Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):475-84. doi: 10.1177/039463201202500217.